EyePoint Pharmaceuticals Prepares for Investor Conferences
![EyePoint Pharmaceuticals Prepares for Investor Conferences](https://investorshangout.com/images/blog/ihnews-EyePoint%20Pharmaceuticals%20Prepares%20for%20Investor%20Conferences.jpg)
EyePoint Pharmaceuticals Prepares for Investor Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company devoted to developing and commercializing innovative therapeutics for patients suffering from serious retinal diseases, has announced its upcoming participation in several key investor conferences.
Upcoming Conferences
The company management will be attending the following notable events:
Morgan Stanley Annual Global Healthcare Conference
This conference will feature one-on-one investor meetings, allowing participants to engage directly with company representatives. The event is scheduled for an upcoming Wednesday.
Baird Global Healthcare Conference
EyePoint Pharmaceuticals will partake in a fireside chat at this conference, offering insights into the company's advances and future plans. This event is set for the coming Tuesday at 4:20 p.m. ET.
Cantor Global Healthcare Conference
During the fireside chat at this conference, EyePoint will further discuss its pipeline and product candidates. The event is planned for a Wednesday at 11:30 a.m. ET.
UBS Virtual Ophthalmology Day
This virtual event will also include a fireside chat with EyePoint Pharmaceuticals, scheduled for a Wednesday at 2:30 p.m. ET.
Webcast Availability
A live webcast and subsequent archived replay of the discussions can be accessed via the Investors section on the company's official website.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in treating serious retinal diseases through innovative methods. The company’s pipeline is anchored by its proprietary bioerodible Durasert E™ technology, which provides sustained intraocular drug delivery. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), represents a significant advancement in treating VEGF-mediated retinal diseases. This investigational drug combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E™ technology to provide sustained drug release.
Current Research and Development
DURAVYU is currently in Phase 2 clinical trials aimed at treating conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are leading causes of vision loss in the United States among older adults. EyePoint expects to commence pivotal Phase 3 trials for wet AMD soon.
Additional Pipeline Products
EyePoint’s pipeline includes EYP-2301, a promising TIE-2 agonist formulation aimed at enhancing outcomes for patients with serious retinal conditions. The Durasert® technology has been successfully deployed in four FDA-approved products, ensuring its efficacy and safety.
Licensing Agreements
Vorolanib, a key component in EyePoint's therapies, is exclusively licensed to the company from Equinox Sciences, part of the Betta Pharmaceuticals group, for treating localized ophthalmic diseases.
Contact Information for Investors and Media
For investor inquiries, please reach out to:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
For media inquiries, contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
Frequently Asked Questions
What is EyePoint Pharmaceuticals known for?
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases.
What are the key upcoming events for EyePoint Pharmaceuticals?
EyePoint is participating in several investor conferences, including events hosted by Morgan Stanley, Baird, Cantor, and UBS.
What is the lead product candidate of EyePoint Pharmaceuticals?
The lead product candidate is DURAVYU™, an investigational sustained delivery treatment for VEGF-mediated retinal diseases.
What technologies does EyePoint Pharmaceuticals utilize?
The company utilizes its proprietary bioerodible Durasert E™ technology to deliver drugs sustainably within the eye.
Where can I find more information about EyePoint Pharmaceuticals?
More information is available on the company's official website and during their upcoming investor presentations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- INVL Technology Announces Investor Presentation and Updates
- WMS Partners with Cordelia Cruises for Onboard Connectivity
- EdReports Launches Pre-K Advisory Board for Quality Curriculum
- Agrochemicals Market Growth Forecast for 2031
- Peer-to-Peer Lending Market Forecast: USD 30.54 Billion Growth
- Cryogenic Insulation Market Growth Forecast: USD 6.30 Billion
- OKX Ventures Backs Space and Time for Blockchain Innovation
- Fortinet Enhances Unified SASE with AI and Sovereign Features
- Ibotta Plans Participation in Major Investor Conferences
- Markforged Launches Revolutionary FX10 Metal Kit